天康生物
(002100)
| 流通市值：86.69亿 | | | 总市值：86.69亿 |
| 流通股本：13.65亿 | | | 总股本：13.65亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,916,826,741.94 | 16,981,074,699.26 | 13,610,370,203.12 | 8,846,725,199.5 |
| 营业收入 | 3,916,826,741.94 | 16,981,074,699.26 | 13,610,370,203.12 | 8,846,725,199.5 |
| 二、营业总成本 | 4,059,490,050.25 | 16,576,749,906.39 | 13,098,483,091.04 | 8,435,393,584.63 |
| 营业成本 | 3,765,570,499.79 | 15,306,380,317.77 | 12,129,821,528.94 | 7,778,921,232.32 |
| 税金及附加 | 14,040,567.08 | 50,070,980.94 | 35,746,600.1 | 24,744,843.34 |
| 销售费用 | 91,711,270.95 | 381,303,993.17 | 294,881,912.31 | 203,244,468.02 |
| 管理费用 | 115,992,429.52 | 517,135,979.19 | 370,467,316.92 | 240,358,633.09 |
| 研发费用 | 37,212,089.08 | 183,506,429.54 | 164,593,119.84 | 112,870,560.82 |
| 财务费用 | 34,963,193.83 | 138,352,205.78 | 102,972,612.94 | 75,253,847.04 |
| 其中:利息费用 | 35,202,406.67 | 159,995,645.74 | 112,841,990.57 | 80,437,905 |
| 其中:利息收入 | 4,097,384.69 | 24,220,746.08 | 18,852,558.07 | 15,044,762.17 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 707,711.39 | 807,450.93 | 354,952.96 | 44,621.09 |
| 加:投资收益 | 110,795.09 | 33,827,765.77 | -9,492,630.37 | -7,276,145.63 |
| 资产处置收益 | -603,747.52 | 587,072.68 | -192,326.85 | -423,913.1 |
| 资产减值损失(新) | -3,364,170.8 | -46,098,106.21 | -4,094,463.56 | -3,186,193.54 |
| 信用减值损失(新) | -20,238,406.54 | -131,543,845.6 | -38,433,637.16 | -25,977,698.18 |
| 其他收益 | 11,061,763.39 | 60,304,441.18 | 41,972,572.82 | 29,438,316.98 |
| 四、营业利润 | -154,989,363.3 | 322,209,571.62 | 502,001,579.92 | 403,950,602.49 |
| 加:营业外收入 | 946,795.55 | 44,585,704.31 | 41,809,484.34 | 38,044,983.52 |
| 减:营业外支出 | 9,645,739.46 | 38,685,876.71 | 28,417,541.11 | 21,011,245.68 |
| 五、利润总额 | -163,688,307.21 | 328,109,399.22 | 515,393,523.15 | 420,984,340.33 |
| 减:所得税费用 | 8,819,858.75 | 27,801,208.75 | 10,528,434.89 | 11,366,210.93 |
| 六、净利润 | -172,508,165.96 | 300,308,190.47 | 504,865,088.26 | 409,618,129.4 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -172,508,165.96 | 300,308,190.47 | 504,865,088.26 | 409,618,129.4 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -163,281,842.86 | 210,634,875.2 | 411,749,486.05 | 338,289,250.51 |
| 少数股东损益 | -9,226,323.1 | 89,673,315.27 | 93,115,602.21 | 71,328,878.89 |
| 扣除非经常损益后的净利润 | -162,022,821.05 | 150,924,111.22 | 381,756,447.68 | 314,216,916.15 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.12 | 0.15 | 0.3 | 0.25 |
| (二)稀释每股收益 | -0.12 | 0.15 | 0.3 | 0.25 |
| 八、其他综合收益 | 77,495,593.39 | 13,946,007.7 | 42,755,441.21 | -25,190,790.19 |
| 归属于母公司股东的其他综合收益 | 80,973,638.4 | 12,595,684.88 | 42,732,831.34 | -25,301,278.85 |
| 九、综合收益总额 | -95,012,572.57 | 314,254,198.17 | 547,620,529.47 | 384,427,339.21 |
| 归属于母公司股东的综合收益总额 | -82,308,204.46 | 223,230,560.08 | 454,482,317.39 | 312,987,971.66 |
| 归属于少数股东的综合收益总额 | -12,704,368.11 | 91,023,638.09 | 93,138,212.08 | 71,439,367.55 |
| 公告日期 | 2026-04-30 | 2026-04-29 | 2025-10-30 | 2025-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |